The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data. (15th March 2020)

• Record Type: Journal Article
• Authors: Luciano, Luigia; Annunziata, Mario; Attolico, Immacolata; Di Raimondo, Francesco; Maggi, Alessandro; Malato, Alessandra; Martino, Bruno; Palmieri, Fausto; Pane, Fabrizio; Sgherza, Nicola; Specchia, Giorgina
• Is Part Of: European journal of haematology. Volume 105:Number 1(2020)
• Page Start: 3
• Page End: 15
• Publication Date: 2020-03-15
• Subjects: chronic myeloid leukemia -- elderly -- frail -- intolerant -- ponatinib -- resistant -- tyrosine kinase inhibitors; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13408
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Development of the highly selective targeted tyrosine kinase inhibitors (TKIs) has expanded the therapeutic options for chronic myeloid leukemia (CML). Patients undergoing TKI therapy should be closely monitored to ensure that the best therapeutic response and quality of life are achieved, and to control suboptimal responses and adverse events. Despite the high rate of response using current first‐line TKIs, treatment failure may still occur, and resistance is considered a challenge in the treatment of patients with CML. The third‐generation TKI, ponatinib, is a potent orally bioavailable pan BCR‐ABL inhibitor that inhibits both wild‐type and mutant BCR‐ABL1 kinase, including the "gatekeeper" T315I mutation, which is resistant to all other currently available TKIs. This paper reviews the effectiveness, feasibility, and safety of ponatinib in the real‐life clinical management of CML. Potential prognostic factors in identifying patients most likely to benefit from ponatinib treatment will be discussed, and case presentations illustrating situations encountered in real‐life clinical practice are described. Ponatinib is effective in patients who have received prior TKIs in clinical studies as well as under real‐life conditions. Nevertheless, the risk/benefit balance must be evaluated for each patient, particularly considering disease state, mutational status, treatment line, intolerance/resistance to prior TKIs, age, frailty, and specific comorbidities.